Overview of current targeted anti-cancer drugs for therapy in onco-hematology

Stefania Crisci, Filomena Amitrano, Mariangela Saggese, Tommaso Muto, Sabrina Sarno, Sara Mele, Pasquale Vitale, Giuseppina Ronga, Massimiliano Berretta, Raffaele Di Francia

Research output: Contribution to journalReview article

Abstract

The upgraded knowledge of tumor biology and microenviroment provides information on differences in neoplastic and normal cells. Thus, the need to target these differences led to the development of novel molecules (targeted therapy) active against the neoplastic cells’ inner workings. There are several types of targeted agents, including Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA (iRNA) molecules and microRNA. In the clinical practice, these new medicines generate a multilayered step in pharmacokinetics (PK), which encompasses a broad individual PK variability, and unpredictable outcomes according to the pharmacogenetics (PG) profile of the patient (e.g., cytochrome P450 enzyme), and to patient characteristics such as adherence to treatment and environmental factors. This review focuses on the use of targeted agents in-human phase I/II/III clinical trials in cancer-hematology. Thus, it outlines the up-to-date anticancer drugs suitable for targeted therapies and the most recent finding in pharmacogenomics related to drug response. Besides, a summary assessment of the genotyping costs has been discussed. Targeted therapy seems to be an effective and less toxic therapeutic approach in onco-hematology. The identification of individual PG profile should be a new resource for oncologists to make treatment decisions for the patients to minimize the toxicity and or inefficacy of therapy. This could allow the clinicians to evaluate benefits and restrictions, regarding costs and applicability, of the most suitable pharmacological approach for performing a tailor-made therapy.

Original languageEnglish
Article number414
JournalMedicina (Lithuania)
Volume55
Issue number8
DOIs
Publication statusPublished - Aug 1 2019

Fingerprint

Hematology
Drug Therapy
Pharmacogenetics
Neoplasms
Therapeutics
Cytochrome P-450 Enzyme System
Pharmacokinetics
Costs and Cost Analysis
Poisons
MicroRNAs
Pharmaceutical Preparations
Monoclonal Antibodies
Clinical Trials
Pharmacology
RNA

Keywords

  • Anticancer mAbs
  • Personalized medicine
  • Pharmacogenomics
  • Tailored therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Overview of current targeted anti-cancer drugs for therapy in onco-hematology. / Crisci, Stefania; Amitrano, Filomena; Saggese, Mariangela; Muto, Tommaso; Sarno, Sabrina; Mele, Sara; Vitale, Pasquale; Ronga, Giuseppina; Berretta, Massimiliano; Di Francia, Raffaele.

In: Medicina (Lithuania), Vol. 55, No. 8, 414, 01.08.2019.

Research output: Contribution to journalReview article

Crisci, S, Amitrano, F, Saggese, M, Muto, T, Sarno, S, Mele, S, Vitale, P, Ronga, G, Berretta, M & Di Francia, R 2019, 'Overview of current targeted anti-cancer drugs for therapy in onco-hematology', Medicina (Lithuania), vol. 55, no. 8, 414. https://doi.org/10.3390/medicina55080414
Crisci, Stefania ; Amitrano, Filomena ; Saggese, Mariangela ; Muto, Tommaso ; Sarno, Sabrina ; Mele, Sara ; Vitale, Pasquale ; Ronga, Giuseppina ; Berretta, Massimiliano ; Di Francia, Raffaele. / Overview of current targeted anti-cancer drugs for therapy in onco-hematology. In: Medicina (Lithuania). 2019 ; Vol. 55, No. 8.
@article{2fde3e5bd1134233adff2b873d36a5b5,
title = "Overview of current targeted anti-cancer drugs for therapy in onco-hematology",
abstract = "The upgraded knowledge of tumor biology and microenviroment provides information on differences in neoplastic and normal cells. Thus, the need to target these differences led to the development of novel molecules (targeted therapy) active against the neoplastic cells’ inner workings. There are several types of targeted agents, including Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA (iRNA) molecules and microRNA. In the clinical practice, these new medicines generate a multilayered step in pharmacokinetics (PK), which encompasses a broad individual PK variability, and unpredictable outcomes according to the pharmacogenetics (PG) profile of the patient (e.g., cytochrome P450 enzyme), and to patient characteristics such as adherence to treatment and environmental factors. This review focuses on the use of targeted agents in-human phase I/II/III clinical trials in cancer-hematology. Thus, it outlines the up-to-date anticancer drugs suitable for targeted therapies and the most recent finding in pharmacogenomics related to drug response. Besides, a summary assessment of the genotyping costs has been discussed. Targeted therapy seems to be an effective and less toxic therapeutic approach in onco-hematology. The identification of individual PG profile should be a new resource for oncologists to make treatment decisions for the patients to minimize the toxicity and or inefficacy of therapy. This could allow the clinicians to evaluate benefits and restrictions, regarding costs and applicability, of the most suitable pharmacological approach for performing a tailor-made therapy.",
keywords = "Anticancer mAbs, Personalized medicine, Pharmacogenomics, Tailored therapy, Tyrosine kinase inhibitors",
author = "Stefania Crisci and Filomena Amitrano and Mariangela Saggese and Tommaso Muto and Sabrina Sarno and Sara Mele and Pasquale Vitale and Giuseppina Ronga and Massimiliano Berretta and {Di Francia}, Raffaele",
year = "2019",
month = "8",
day = "1",
doi = "10.3390/medicina55080414",
language = "English",
volume = "55",
journal = "Medicina",
issn = "1010-660X",
publisher = "Kauno Medicinos Universitetas",
number = "8",

}

TY - JOUR

T1 - Overview of current targeted anti-cancer drugs for therapy in onco-hematology

AU - Crisci, Stefania

AU - Amitrano, Filomena

AU - Saggese, Mariangela

AU - Muto, Tommaso

AU - Sarno, Sabrina

AU - Mele, Sara

AU - Vitale, Pasquale

AU - Ronga, Giuseppina

AU - Berretta, Massimiliano

AU - Di Francia, Raffaele

PY - 2019/8/1

Y1 - 2019/8/1

N2 - The upgraded knowledge of tumor biology and microenviroment provides information on differences in neoplastic and normal cells. Thus, the need to target these differences led to the development of novel molecules (targeted therapy) active against the neoplastic cells’ inner workings. There are several types of targeted agents, including Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA (iRNA) molecules and microRNA. In the clinical practice, these new medicines generate a multilayered step in pharmacokinetics (PK), which encompasses a broad individual PK variability, and unpredictable outcomes according to the pharmacogenetics (PG) profile of the patient (e.g., cytochrome P450 enzyme), and to patient characteristics such as adherence to treatment and environmental factors. This review focuses on the use of targeted agents in-human phase I/II/III clinical trials in cancer-hematology. Thus, it outlines the up-to-date anticancer drugs suitable for targeted therapies and the most recent finding in pharmacogenomics related to drug response. Besides, a summary assessment of the genotyping costs has been discussed. Targeted therapy seems to be an effective and less toxic therapeutic approach in onco-hematology. The identification of individual PG profile should be a new resource for oncologists to make treatment decisions for the patients to minimize the toxicity and or inefficacy of therapy. This could allow the clinicians to evaluate benefits and restrictions, regarding costs and applicability, of the most suitable pharmacological approach for performing a tailor-made therapy.

AB - The upgraded knowledge of tumor biology and microenviroment provides information on differences in neoplastic and normal cells. Thus, the need to target these differences led to the development of novel molecules (targeted therapy) active against the neoplastic cells’ inner workings. There are several types of targeted agents, including Small Molecules Inhibitors (SMIs), monoclonal antibodies (mAbs), interfering RNA (iRNA) molecules and microRNA. In the clinical practice, these new medicines generate a multilayered step in pharmacokinetics (PK), which encompasses a broad individual PK variability, and unpredictable outcomes according to the pharmacogenetics (PG) profile of the patient (e.g., cytochrome P450 enzyme), and to patient characteristics such as adherence to treatment and environmental factors. This review focuses on the use of targeted agents in-human phase I/II/III clinical trials in cancer-hematology. Thus, it outlines the up-to-date anticancer drugs suitable for targeted therapies and the most recent finding in pharmacogenomics related to drug response. Besides, a summary assessment of the genotyping costs has been discussed. Targeted therapy seems to be an effective and less toxic therapeutic approach in onco-hematology. The identification of individual PG profile should be a new resource for oncologists to make treatment decisions for the patients to minimize the toxicity and or inefficacy of therapy. This could allow the clinicians to evaluate benefits and restrictions, regarding costs and applicability, of the most suitable pharmacological approach for performing a tailor-made therapy.

KW - Anticancer mAbs

KW - Personalized medicine

KW - Pharmacogenomics

KW - Tailored therapy

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85070774593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070774593&partnerID=8YFLogxK

U2 - 10.3390/medicina55080414

DO - 10.3390/medicina55080414

M3 - Review article

C2 - 31357735

AN - SCOPUS:85070774593

VL - 55

JO - Medicina

JF - Medicina

SN - 1010-660X

IS - 8

M1 - 414

ER -